Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Roy First

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Transplantation|September 3, 2010
Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathyAntonio Guasch, Prabir Roy-Chaudhury, E Steve Woodle, et al.
Therapeutic Drug Monitoring|August 28, 2014
Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantationSonia Lin, Alice K Henning, Fatemeh Akhlaghi, et al.
Annals of Surgery|October 22, 2008
A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapyE Steve Woodle, M Roy First, John Pirsch, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 12, 2002
The role of immunosuppression in lymphomaJennifer Trofe, Joseph F Buell, M Roy First, et al.
Transplantation|July 16, 2008
Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month resultsPaul Bolin, Fuad S Shihab, Laura Mulloy, et al.
Transplantation|May 9, 2009
De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general populationYun Miao, Jason J Everly, Thomas G Gross, et al.
Transplantation|February 14, 2014
Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipientsHélio Tedesco Silva, Harold C Yang, Herwig-Ulf Meier-Kriesche, et al.
The New England Journal of Medicine|May 20, 2011
Alemtuzumab induction in renal transplantationMichael J Hanaway, E Steve Woodle, Shamkant Mulgaonkar, et al.
Progress in Transplantation (Aliso Viejo, Calif.)|October 22, 2004
Posttransplant malignancyJennifer Trofe, Thomas M Beebe, Joseph F Buell, et al.
Transplantation|October 14, 2004
Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphomaJennifer Trofe, Joseph F Buell, E Steve Woodle, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Transplantation|September 3, 2010
Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathyAntonio Guasch, Prabir Roy-Chaudhury, E Steve Woodle, et al.
Therapeutic Drug Monitoring|August 28, 2014
Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantationSonia Lin, Alice K Henning, Fatemeh Akhlaghi, et al.
Annals of Surgery|October 22, 2008
A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapyE Steve Woodle, M Roy First, John Pirsch, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 12, 2002
The role of immunosuppression in lymphomaJennifer Trofe, Joseph F Buell, M Roy First, et al.
Transplantation|July 16, 2008
Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month resultsPaul Bolin, Fuad S Shihab, Laura Mulloy, et al.
Transplantation|May 9, 2009
De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general populationYun Miao, Jason J Everly, Thomas G Gross, et al.
Transplantation|February 14, 2014
Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipientsHélio Tedesco Silva, Harold C Yang, Herwig-Ulf Meier-Kriesche, et al.
The New England Journal of Medicine|May 20, 2011
Alemtuzumab induction in renal transplantationMichael J Hanaway, E Steve Woodle, Shamkant Mulgaonkar, et al.
Progress in Transplantation (Aliso Viejo, Calif.)|October 22, 2004
Posttransplant malignancyJennifer Trofe, Thomas M Beebe, Joseph F Buell, et al.
Transplantation|October 14, 2004
Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphomaJennifer Trofe, Joseph F Buell, E Steve Woodle, et al.
Pageof 6